カテゴリー： QYResearch, 世界, 医療/バイオ

自家生物製剤のグローバル市場2023年：脂肪組織、血漿、その他

◆英語タイトル：Global Autologous Biologics Market Research Report 2023

QYResearchが発行した調査報告書（QYR23MA7646）◆商品コード：QYR23MA7646
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2023年3月
◆ページ数：92
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の自家生物製剤市場について調査・分析し、世界の自家生物製剤市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（脂肪組織、血漿、その他）、用途別セグメント分析（病院、外来センター、研究センター）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Vericel Corporation、BioTime, Inc.、Pharmicell Co.、BrainStorm Cell Therapeutics、Opexa Therapeutics, Inc、Pharmicell Co., Inc、Neostem、Dendreon Corporation、Regenexx、Cytori Therapeuticsなどが含まれています。世界の自家生物製剤市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、自家生物製剤市場規模を推定する際に考慮しました。

・自家生物製剤市場の概要
- 製品の定義
- 自家生物製剤のタイプ別セグメント
- 世界の自家生物製剤市場規模：タイプ別分析（脂肪組織、血漿、その他）
- 自家生物製剤の用途別セグメント
- 世界の自家生物製剤市場規模：用途別分析（病院、外来センター、研究センター）
- 世界の自家生物製剤市場規模予測（2018年-2029年）
- 自家生物製剤の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 自家生物製剤市場の競争状況およびトレンド

・自家生物製剤の地域別市場規模
- 北米の自家生物製剤市場規模（2018年-2029年）
- アメリカの自家生物製剤市場規模（2018年-2029年）
- ヨーロッパの自家生物製剤市場規模（2018年-2029年）
- アジア太平洋の自家生物製剤市場規模（2018年-2029年）
- 中国の自家生物製剤市場規模（2018年-2029年）
- 日本の自家生物製剤市場規模（2018年-2029年）
- 韓国の自家生物製剤市場規模（2018年-2029年）
- インドの自家生物製剤市場規模（2018年-2029年）
- オーストラリアの自家生物製剤市場規模（2018年-2029年）
- 中南米の自家生物製剤市場規模（2018年-2029年）
- 中東・アフリカの自家生物製剤市場規模（2018年-2029年）

・タイプ別セグメント：脂肪組織、血漿、その他
- 世界の自家生物製剤のタイプ別販売量（2018年-2023年）
- 世界の自家生物製剤のタイプ別売上（2018年-2023年）
- 世界の自家生物製剤のタイプ別価格

・用途別セグメント：病院、外来センター、研究センター
- 世界の自家生物製剤の用途別販売量（2018年-2023年）
- 世界の自家生物製剤の用途別売上（2018年-2023年）
- 世界の自家生物製剤の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Vericel Corporation、BioTime, Inc.、Pharmicell Co.、BrainStorm Cell Therapeutics、Opexa Therapeutics, Inc、Pharmicell Co., Inc、Neostem、Dendreon Corporation、Regenexx、Cytori Therapeutics

・産業チェーンと販売チャネルの分析
- 自家生物製剤産業チェーン分析
- 自家生物製剤の主要原材料
- 自家生物製剤の販売チャネル
- 自家生物製剤のディストリビューター
- 自家生物製剤の主要顧客

・自家生物製剤市場ダイナミクス
- 自家生物製剤の業界動向
- 自家生物製剤市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Highlights
The global Autologous Biologics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Autologous Biologics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Autologous Biologics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Autologous Biologics include Vericel Corporation, BioTime, Inc., Pharmicell Co., BrainStorm Cell Therapeutics, Opexa Therapeutics, Inc, Pharmicell Co., Inc, Neostem, Dendreon Corporation and Regenexx, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Autologous Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Autologous Biologics.
The Autologous Biologics market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Autologous Biologics market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Autologous Biologics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Vericel Corporation
BioTime, Inc.
Pharmicell Co.
BrainStorm Cell Therapeutics
Opexa Therapeutics, Inc
Pharmicell Co., Inc
Neostem
Dendreon Corporation
Regenexx
Cytori Therapeutics
Segment by Type
Adipose Tissue
Plasma
Others
Segment by Application
Hospitals
Ambulatory Centers
Research Centers
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Autologous Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Autologous Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Autologous Biologics Market Overview
1.1 Product Overview and Scope of Autologous Biologics
1.2 Autologous Biologics Segment by Type
1.2.1 Global Autologous Biologics Market Value Comparison by Type (2023-2029)
1.2.2 Adipose Tissue
1.2.3 Plasma
1.2.4 Others
1.3 Autologous Biologics Segment by Application
1.3.1 Global Autologous Biologics Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Ambulatory Centers
1.3.4 Research Centers
1.4 Global Autologous Biologics Market Size Estimates and Forecasts
1.4.1 Global Autologous Biologics Revenue 2018-2029
1.4.2 Global Autologous Biologics Sales 2018-2029
1.4.3 Global Autologous Biologics Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Autologous Biologics Market Competition by Manufacturers
2.1 Global Autologous Biologics Sales Market Share by Manufacturers (2018-2023)
2.2 Global Autologous Biologics Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Autologous Biologics Average Price by Manufacturers (2018-2023)
2.4 Global Autologous Biologics Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Autologous Biologics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Autologous Biologics, Product Type & Application
2.7 Autologous Biologics Market Competitive Situation and Trends
2.7.1 Autologous Biologics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Autologous Biologics Players Market Share by Revenue
2.7.3 Global Autologous Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Autologous Biologics Retrospective Market Scenario by Region
3.1 Global Autologous Biologics Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Autologous Biologics Global Autologous Biologics Sales by Region: 2018-2029
3.2.1 Global Autologous Biologics Sales by Region: 2018-2023
3.2.2 Global Autologous Biologics Sales by Region: 2024-2029
3.3 Global Autologous Biologics Global Autologous Biologics Revenue by Region: 2018-2029
3.3.1 Global Autologous Biologics Revenue by Region: 2018-2023
3.3.2 Global Autologous Biologics Revenue by Region: 2024-2029
3.4 North America Autologous Biologics Market Facts & Figures by Country
3.4.1 North America Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Autologous Biologics Sales by Country (2018-2029)
3.4.3 North America Autologous Biologics Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Autologous Biologics Market Facts & Figures by Country
3.5.1 Europe Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Autologous Biologics Sales by Country (2018-2029)
3.5.3 Europe Autologous Biologics Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Autologous Biologics Market Facts & Figures by Country
3.6.1 Asia Pacific Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Autologous Biologics Sales by Country (2018-2029)
3.6.3 Asia Pacific Autologous Biologics Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Autologous Biologics Market Facts & Figures by Country
3.7.1 Latin America Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Autologous Biologics Sales by Country (2018-2029)
3.7.3 Latin America Autologous Biologics Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Autologous Biologics Market Facts & Figures by Country
3.8.1 Middle East and Africa Autologous Biologics Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Autologous Biologics Sales by Country (2018-2029)
3.8.3 Middle East and Africa Autologous Biologics Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Autologous Biologics Sales by Type (2018-2029)
4.1.1 Global Autologous Biologics Sales by Type (2018-2023)
4.1.2 Global Autologous Biologics Sales by Type (2024-2029)
4.1.3 Global Autologous Biologics Sales Market Share by Type (2018-2029)
4.2 Global Autologous Biologics Revenue by Type (2018-2029)
4.2.1 Global Autologous Biologics Revenue by Type (2018-2023)
4.2.2 Global Autologous Biologics Revenue by Type (2024-2029)
4.2.3 Global Autologous Biologics Revenue Market Share by Type (2018-2029)
4.3 Global Autologous Biologics Price by Type (2018-2029)
5 Segment by Application
5.1 Global Autologous Biologics Sales by Application (2018-2029)
5.1.1 Global Autologous Biologics Sales by Application (2018-2023)
5.1.2 Global Autologous Biologics Sales by Application (2024-2029)
5.1.3 Global Autologous Biologics Sales Market Share by Application (2018-2029)
5.2 Global Autologous Biologics Revenue by Application (2018-2029)
5.2.1 Global Autologous Biologics Revenue by Application (2018-2023)
5.2.2 Global Autologous Biologics Revenue by Application (2024-2029)
5.2.3 Global Autologous Biologics Revenue Market Share by Application (2018-2029)
5.3 Global Autologous Biologics Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Vericel Corporation
6.1.1 Vericel Corporation Corporation Information
6.1.2 Vericel Corporation Description and Business Overview
6.1.3 Vericel Corporation Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Vericel Corporation Autologous Biologics Product Portfolio
6.1.5 Vericel Corporation Recent Developments/Updates
6.2 BioTime, Inc.
6.2.1 BioTime, Inc. Corporation Information
6.2.2 BioTime, Inc. Description and Business Overview
6.2.3 BioTime, Inc. Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.2.4 BioTime, Inc. Autologous Biologics Product Portfolio
6.2.5 BioTime, Inc. Recent Developments/Updates
6.3 Pharmicell Co.
6.3.1 Pharmicell Co. Corporation Information
6.3.2 Pharmicell Co. Description and Business Overview
6.3.3 Pharmicell Co. Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pharmicell Co. Autologous Biologics Product Portfolio
6.3.5 Pharmicell Co. Recent Developments/Updates
6.4 BrainStorm Cell Therapeutics
6.4.1 BrainStorm Cell Therapeutics Corporation Information
6.4.2 BrainStorm Cell Therapeutics Description and Business Overview
6.4.3 BrainStorm Cell Therapeutics Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 BrainStorm Cell Therapeutics Autologous Biologics Product Portfolio
6.4.5 BrainStorm Cell Therapeutics Recent Developments/Updates
6.5 Opexa Therapeutics, Inc
6.5.1 Opexa Therapeutics, Inc Corporation Information
6.5.2 Opexa Therapeutics, Inc Description and Business Overview
6.5.3 Opexa Therapeutics, Inc Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Opexa Therapeutics, Inc Autologous Biologics Product Portfolio
6.5.5 Opexa Therapeutics, Inc Recent Developments/Updates
6.6 Pharmicell Co., Inc
6.6.1 Pharmicell Co., Inc Corporation Information
6.6.2 Pharmicell Co., Inc Description and Business Overview
6.6.3 Pharmicell Co., Inc Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Pharmicell Co., Inc Autologous Biologics Product Portfolio
6.6.5 Pharmicell Co., Inc Recent Developments/Updates
6.7 Neostem
6.6.1 Neostem Corporation Information
6.6.2 Neostem Description and Business Overview
6.6.3 Neostem Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Neostem Autologous Biologics Product Portfolio
6.7.5 Neostem Recent Developments/Updates
6.8 Dendreon Corporation
6.8.1 Dendreon Corporation Corporation Information
6.8.2 Dendreon Corporation Description and Business Overview
6.8.3 Dendreon Corporation Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Dendreon Corporation Autologous Biologics Product Portfolio
6.8.5 Dendreon Corporation Recent Developments/Updates
6.9 Regenexx
6.9.1 Regenexx Corporation Information
6.9.2 Regenexx Description and Business Overview
6.9.3 Regenexx Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Regenexx Autologous Biologics Product Portfolio
6.9.5 Regenexx Recent Developments/Updates
6.10 Cytori Therapeutics
6.10.1 Cytori Therapeutics Corporation Information
6.10.2 Cytori Therapeutics Description and Business Overview
6.10.3 Cytori Therapeutics Autologous Biologics Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Cytori Therapeutics Autologous Biologics Product Portfolio
6.10.5 Cytori Therapeutics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Autologous Biologics Industry Chain Analysis
7.2 Autologous Biologics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Autologous Biologics Production Mode & Process
7.4 Autologous Biologics Sales and Marketing
7.4.1 Autologous Biologics Sales Channels
7.4.2 Autologous Biologics Distributors
7.5 Autologous Biologics Customers
8 Autologous Biologics Market Dynamics
8.1 Autologous Biologics Industry Trends
8.2 Autologous Biologics Market Drivers
8.3 Autologous Biologics Market Challenges
8.4 Autologous Biologics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 自家生物製剤のグローバル市場2023年：脂肪組織、血漿、その他(Global Autologous Biologics Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 骨&関節における再生医療のグローバル市場展望 2023年-2029年：同種骨治療、自家骨治療、移植骨代替療法、整形外科&関節疾患治療
  • 自己輸血製品のグローバル市場予測2023-2029
  • 生物工学による代用皮膚のグローバル市場2023年：同種無細胞、異種、同種細胞、自家細胞
  • 世界のCD47（IAP）市場インサイト及び予測（CD47モノクローナル抗体、CD47ダブル抗体、CD47融合タンパク質）
  • 世界の地図状萎縮市場インサイト及び予測（60歳以上、75歳以上）